CORE C (Biostatistics) will reside within the University of Pittsburgh Cancer Institute's (UPCl) Biostatistics Facility, which provides clinical and basic-science investigators in UPCl with statistical expertise in design, analysis, and reporting of cancer-related research studies. These cover basic-science studies;phase I and phase II oncology clinical trials;epidemiologic studies, including those related to cancer prevention and awareness;and investigations of behavioral and health sequelae of cancer treatment. In its role as Core C for this SPORE, the Biostatistics Core will support all four research projects. We will collaborate with investigators on statistical aspects of the design of in vitro and in vivo laboratory-based studies as new data come to light, and perform both exploratory and confirmatory statistical analyses of the resulting data from key experiments in Projects 1-4. We will perform interim analyses of safety for the SPORE's clinical trials (Projects 2, 3, &4), and final analyses of their data on safety, immune response, and treatment efficacy. We will contribute to the review of the SPORE's developmental research-program proposals, and provide statistical support to those that are funded. We will provide statistical support to the career-development awardees. We will work with the project investigators, with Core D (Informatics), and with UPCl Clinical Research Services, a component of Core A, to ensure that the requisite laboratory and clinical-trial data are available for statistical analyses. We will collaborate with the project investigators in writing and preparing progress reports, abstracts, manuscripts, and presentations. We will also conduct methodological research motivated by the SPORE projects to improve the statistical efficiency in the study design and analysis.
Members of the biostatistics core have considerable statistical expertise and experiences in the design and analysis of both laboratory and clinical data. We have long standing collaboration history with the investigators of the Melanoma program in UPCl and have worked closely with the SPORE investigators during the last funding period. We will provide integrated support for the design and analysis of all SPORE studies in the next funding period of the SPORE.
|Retseck, Janet; VanderWeele, Robert; Lin, Hui-Min et al. (2016) Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer 4:38|
|Scharping, Nicole E; Menk, Ashley V; Moreci, Rebecca S et al. (2016) The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity 45:374-88|
|Villalona-Calero, Miguel A; Duan, Wenrui; Zhao, Weiqiang et al. (2016) Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. J Natl Cancer Inst 108:|
|Bengsch, Bertram; Johnson, Andy L; Kurachi, Makoto et al. (2016) Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity 45:358-73|
|Sottile, Rosa; Pangigadde, Pradeepa N; Tan, Thomas et al. (2016) HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol 46:409-19|
|Fan, Yiping; Lee, Seungjae; Wu, Gang et al. (2016) Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol 136:339-42|
|Davar, Diwakar; Kirkwood, John M (2016) Adjuvant Therapy of Melanoma. Cancer Treat Res 167:181-208|
|Butterfield, Lisa H (2016) Lessons learned from cancer vaccine trials and target antigen choice. Cancer Immunol Immunother 65:805-12|
|Zarour, Hassane M (2016) Reversing T-cell Dysfunction and Exhaustion in Cancer. Clin Cancer Res 22:1856-64|
|Blackler, Ryan J; Evans, Dylan W; Smith, David F et al. (2016) Single-chain antibody-fragment M6P-1 possesses a mannose 6-phosphate monosaccharide-specific binding pocket that distinguishes N-glycan phosphorylation in a branch-specific mannerâ€ . Glycobiology 26:181-92|
Showing the most recent 10 out of 162 publications